Preliminary report of transmitted drug resistance to integrase strand chain transfer inhibitors in treatment-naïve HIV infected patients

Diagn Microbiol Infect Dis. 2023 Dec;107(4):116083. doi: 10.1016/j.diagmicrobio.2023.116083. Epub 2023 Sep 7.

Abstract

Transmitted Resistance exists in a newly diagnosed person who has not yet started their treatment. Our objective was to obtain a profile of HIV-1 resistance to integrase inhibitors in newly diagnosed treatment-naïve patients. Fifty people newly diagnosed with HIV-1 infection who had never received antiretroviral treatment were recruited. The complete integrase gene was amplified by nested RTPCR and the sequences obtained were analyzed with the ReCall and HIVdb v9.0. The overall prevalence transmitted due to mutations with some impact on integrase strand transfer inhibitors (INSTI) activity during the study period was 8%. The major E138K mutation was detected in only 1 patient and the secondary G163R mutation was detected in the other 3. The transmitted resistance for the first generation INSTI was 8% and for the second generation it was 0%. In Chile the resistance transmitted to INSTI is low and it is in according values detect in other part of the world.

Keywords: HIV genotyping report; HIV/AIDS; Integrase strand chain transfer inhibitors; Transmitted genetic resistance; Virologic failure.

MeSH terms

  • Drug Resistance, Viral / genetics
  • Genotype
  • HIV Infections* / epidemiology
  • HIV Integrase Inhibitors* / pharmacology
  • HIV Integrase Inhibitors* / therapeutic use
  • HIV Integrase* / genetics
  • Humans
  • Mutation

Substances

  • HIV Integrase Inhibitors
  • HIV Integrase